Innovative Medtech Inc Financials

IMTH

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2025 Currency USD FYE June

This page shows Innovative Medtech Inc (IMTH) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Neutral

4/9

Innovative Medtech Inc passes 4 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Cash-Backed

2.25x

For every $1 of reported earnings, Innovative Medtech Inc generates $2.25 in operating cash flow ($2.9M OCF vs $1.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage At Risk

-32.1x

Innovative Medtech Inc earns $-32.1 in operating income for every $1 of interest expense (-$2.7M vs $85K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

N/A

Free Cash Flow

N/A

Net Income

$1.3M

YoY+116.0%

Innovative Medtech Inc reported $1.3M in net income in fiscal year 2025. This represents an increase of 116.0% from the prior year.

EPS (Diluted)

$0.03

YoY+109.1%

Innovative Medtech Inc earned $0.03 per diluted share (EPS) in fiscal year 2025. This represents an increase of 109.1% from the prior year.

Cash & Debt

$14K

YoY+1459.7%

5Y CAGR+77.8%

10Y CAGR+12.2%

Innovative Medtech Inc held $14K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

54M

YoY+124.9%

Innovative Medtech Inc had 54M shares outstanding in fiscal year 2025. This represents an increase of 124.9% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

IMTH Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	$1.8M+5.8%	$1.7M+32.9%	$1.3M+271.7%	$349K	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$360K+1364.6%	$25K-97.5%	$973K+4.2%	$933K+215.9%	$295K+226.3%	$91K
Operating Income	-$2.7M+31.8%	-$4.0M-10.5%	-$3.6M+80.1%	-$18.3M-2475.6%	-$709K-87.3%	-$378K
Interest Expense	$85K-2.9%	$87K-43.6%	$155K-15.1%	$183K+5.9%	$172K-17.3%	$208K
Income Tax	$0	$0	N/A	N/A	N/A	N/A
Net Income	$1.3M+116.0%	-$7.9M-117.6%	-$3.6M+79.8%	-$18.1M-453.1%	-$3.3M-566.7%	-$490K
EPS (Diluted)	$0.03+109.1%	$-0.33	N/A	N/A	N/A	N/A

Metric	Q2'25	Q3'25	Q3'25	Q1'25	Q2'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	$428K-6.1%	$456K+0.3%	$455K+5.2%	$433K-10.0%	$481K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	$17K-84.9%	$115K+127.1%	-$426K-294.7%	$219K+3902.8%	$5K-97.6%	$226K
Operating Income	N/A	-$57K+94.7%	-$1.1M-29.9%	-$827K+71.5%	-$2.9M-234.9%	-$865K-822.0%	-$94K+36.1%	-$147K
Interest Expense	N/A	$42K+41.9%	$30K+1.2%	$30K+20.4%	$25K-19.9%	$31K+196.5%	$10K-52.7%	$22K
Income Tax	N/A	$0	$0	N/A	N/A	$0	$0	N/A
Net Income	N/A	-$89K+92.1%	-$1.1M-27.3%	-$884K+86.8%	-$6.7M-633.7%	-$910K-383.6%	-$188K-14.0%	-$165K
EPS (Diluted)	N/A	$0.00+100.0%	$-0.04	N/A	N/A	$-0.04-300.0%	$-0.01	N/A

IMTH Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$250K-61.6%	$652K-85.3%	$4.4M-7.3%	$4.8M-6.5%	$5.1M+669925.7%	$766
Current Assets	$23K-91.9%	$284K-27.9%	$394K-23.5%	$515K-22.3%	$663K+86417.2%	$766
Cash & Equivalents	$14K+1459.7%	$873-22.1%	$1K-99.6%	$301K-30.5%	$433K+56484.2%	$766
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0-100.0%	$161K-28.3%	$225K+20.6%	$186K+4.3%	$179K	$0
Goodwill	N/A	$0-100.0%	$178K0.0%	$178K-94.7%	$3.4M	$0
Total Liabilities	$1.3M-78.8%	$6.1M+6.5%	$5.8M-7.3%	$6.2M+19.7%	$5.2M+28.4%	$4.0M
Current Liabilities	$1.3M-68.2%	$4.1M+14.7%	$3.6M-7.2%	$3.9M+38.0%	$2.8M-30.9%	$4.0M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$14K-92.8%	$201K
Total Equity	-$1.1M+80.8%	-$5.5M-319.1%	-$1.3M+7.2%	-$1.4M-2443.9%	-$55K+98.6%	-$4.0M
Retained Earnings	-$43.3M+2.8%	-$44.6M-21.7%	-$36.6M-11.1%	-$33.0M-121.1%	-$14.9M-28.0%	-$11.7M

Metric	Q2'25	Q3'25	Q3'25	Q1'25	Q2'24	Q3'24	Q2'24	Q1'24
Total Assets	$250K-76.4%	$1.1M-6.1%	$1.1M-11.5%	$1.3M+96.2%	$652K-86.0%	$4.7M+7.6%	$4.3M-5.3%	$4.6M
Current Assets	$23K-90.9%	$250K-5.8%	$266K-26.0%	$359K+26.6%	$284K-58.7%	$688K+130.4%	$298K-39.4%	$492K
Cash & Equivalents	$14K+3779.2%	$351+258.2%	$98-99.9%	$174K+19864.8%	$873+42.4%	$613+6.1%	$578-99.8%	$257K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$0	N/A	N/A	$166K+3.4%	$161K-27.0%	$221K+12.7%	$196K-12.9%	$225K
Goodwill	N/A	N/A	N/A	N/A	$0-100.0%	$178K0.0%	$178K0.0%	$178K
Total Liabilities	$1.3M-78.1%	$6.0M-0.4%	$6.0M-5.2%	$6.3M+2.8%	$6.1M+1.6%	$6.0M+1.1%	$6.0M-0.9%	$6.0M
Current Liabilities	$1.3M-67.5%	$4.0M+0.6%	$4.0M-6.5%	$4.3M+4.1%	$4.1M+3.9%	$3.9M+3.8%	$3.8M-0.6%	$3.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$1.1M+78.5%	-$4.9M-1.0%	-$4.8M+3.6%	-$5.0M+8.3%	-$5.5M-298.3%	-$1.4M+16.0%	-$1.6M-13.0%	-$1.5M
Retained Earnings	-$43.3M+7.2%	-$46.7M-0.2%	-$46.6M-2.5%	-$45.4M-2.0%	-$44.6M-17.6%	-$37.9M-2.5%	-$37.0M-0.5%	-$36.8M

IMTH Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$2.9M+1658.6%	-$183K-8.4%	-$169K+71.0%	-$583K-2174.3%	$28K+157.1%	-$49K
Capital Expenditures	N/A	$51K+302.4%	$13K-72.8%	$46K	N/A	N/A
Free Cash Flow	N/A	-$234K-28.8%	-$182K+71.1%	-$629K	N/A	N/A
Investing Cash Flow	N/A	-$51K-1037.9%	$5K+153.0%	-$10K+99.3%	-$1.6M	$0
Financing Cash Flow	N/A	$190K+857.1%	$20K-95.7%	$461K-76.6%	$2.0M+3832.8%	$50K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q3'25	Q3'25	Q1'25	Q2'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$2.9M+16662.7%	-$18K+83.3%	-$106K-444.5%	$31K-40.4%	$52K+409.6%	-$17K+90.9%	-$183K-420.1%	-$35K
Capital Expenditures	N/A	N/A	N/A	$12K+125.9%	-$45K	$0	$0-100.0%	$95K
Free Cash Flow	N/A	N/A	N/A	$19K+166.3%	$7K+143.3%	-$17K+90.9%	-$183K-40.3%	-$130K
Investing Cash Flow	N/A	N/A	N/A	-$12K-125.9%	$45K	$0	$0+100.0%	-$95K
Financing Cash Flow	N/A	N/A	$77K+86.5%	$41K+5694.7%	$716-98.2%	$39K+149.0%	-$79K-134.6%	$229K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

IMTH Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-219.4%-9.3pp	-210.1%+1196.9pp	-1407.0%-1204.0pp	-203.0%	N/A
Net Margin	N/A	-435.0%-223.5pp	-211.5%+1180.2pp	-1391.7%-456.5pp	-935.1%	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	506.7%+1724.6pp	-1217.8%-1135.9pp	-82.0%+294.2pp	-376.2%-312.6pp	-63.6%+63865.2pp	-63928.8%
Current Ratio	0.02-0.1	0.07-0.0	0.11-0.0	0.13-0.1	0.24+0.2	0.00
Debt-to-Equity	-1.24-0.1	-1.12+3.3	-4.40-4.4	0.00+0.3	-0.26-0.2	-0.05
FCF Margin	N/A	-12.8%-2.3pp	-10.5%+38.0pp	-48.5%	N/A	N/A

Metric	Q2'25	Q3'25	Q3'25	Q1'25	Q2'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-193.0%+441.9pp	-634.9%-444.9pp	-190.1%-168.4pp	-21.7%+8.8pp	-30.5%
Net Margin	N/A	N/A	N/A	-206.3%+1256.6pp	-1462.8%-1262.9pp	-199.9%-156.4pp	-43.5%-9.1pp	-34.3%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-8.3%+91.0pp	-99.3%-30.2pp	-69.1%+955.0pp	-1024.1%-1004.6pp	-19.5%-15.2pp	-4.3%-0.7pp	-3.6%
Current Ratio	0.02-0.0	0.060.0	0.07-0.0	0.08+0.0	0.07-0.1	0.17+0.1	0.08-0.1	0.13
Debt-to-Equity	-1.24-0.0	-1.22+0.0	-1.23+0.0	-1.25-0.1	-1.12+3.3	-4.38-0.7	-3.64+0.5	-4.15
FCF Margin	N/A	N/A	N/A	4.5%+2.9pp	1.6%+5.3pp	-3.7%+38.6pp	-42.3%-15.2pp	-27.1%

Note: Shareholder equity is negative (-$1.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Cardiac Biotech Solutions Inc CBSC

$6.6M

Encision ECIA

$6.4M

Reflect Scientfc RSCF

$5.1M

Standard Dental Labs Inc TUTH

$3.2M

United Health Pr UEEC

$18.8M

Frequently Asked Questions

Is Innovative Medtech Inc profitable?

Yes, Innovative Medtech Inc (IMTH) reported a net income of $1.3M in fiscal year 2025.

What is Innovative Medtech Inc's earnings per share (EPS)?

Innovative Medtech Inc (IMTH) reported diluted earnings per share of $0.03 for fiscal year 2025. This represents a 109.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Innovative Medtech Inc's operating cash flow?

Innovative Medtech Inc (IMTH) generated $2.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Innovative Medtech Inc's total assets?

Innovative Medtech Inc (IMTH) had $250K in total assets as of fiscal year 2025, including both current and long-term assets.

How many shares does Innovative Medtech Inc have outstanding?

Innovative Medtech Inc (IMTH) had 54M shares outstanding as of fiscal year 2025.

What is Innovative Medtech Inc's current ratio?

Innovative Medtech Inc (IMTH) had a current ratio of 0.02 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Innovative Medtech Inc's debt-to-equity ratio?

Innovative Medtech Inc (IMTH) had a debt-to-equity ratio of -1.24 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Innovative Medtech Inc's return on assets (ROA)?

Innovative Medtech Inc (IMTH) had a return on assets of 506.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Innovative Medtech Inc's debt-to-equity ratio negative or unusual?

Innovative Medtech Inc (IMTH) has negative shareholder equity of -$1.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Innovative Medtech Inc's Piotroski F-Score?

Innovative Medtech Inc (IMTH) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Innovative Medtech Inc's earnings high quality?

Innovative Medtech Inc (IMTH) has an earnings quality ratio of 2.25x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Innovative Medtech Inc cover its interest payments?

Innovative Medtech Inc (IMTH) has an interest coverage ratio of -32.1x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.